Please read this first

The author of this page is just a shareholder, not affiliated with either company or their stakeholders in any way, shape, or form. This is not company material, and it is not investment advice.

NASDAQ: SHFS SHF Holdings / Safe Harbor Financial + Opifex Media PR: Oct 26, 2026 • GlobeNewswire
Due diligence • Read the primary source

Did everyone read the actual PR?
Some HUGE nuggets buried in there.

The headline said “non-binding term sheet.” The fine print says more: a dilution pause, a $50M floor, a CVR for holders, and Series B converting at close. The plan for Nasdaq compliance is the merger, not a reverse split.

$50M+Opifex valuation floorSubject to independent valuation + fairness opinion
85 / 15Opifex / SHFS holdersSHFS slice adjustable 12.5% – 17.5%
DILUTION PAUSEDNo new shares printed until closingSee §2 below
Apr 19, 2027Nasdaq deadline + target close$1 bid-price extension granted Oct 20th

Deal terms from one primary source: GlobeNewswire, Oct 26, 2026. Everything below traces to it, unless labeled scenario math.

01 - The valuation
$50M MINIMUM

And that's the floor, not pie in the sky hopium. The terms of the LOI state that the minimum valuation for Opifex will be $50 million. This is key to how we get to a $1+ share price (all the math below).

Opifex will deliver a proposed valuation, together with its financial statements and supporting analysis, within 15 business days. The term sheet contemplates an Opifex valuation of not less than $50 million, subject to an independent valuation and fairness opinion delivered to Safe Harbor's Board of Directors.

GlobeNewswire PR, Oct 26, 2026 (verbatim)
Floor, not a guess

Not less than $50 million is written into the term sheet, subject to an independent valuation and fairness opinion.

Due in 15 business days

The proposed valuation, financial statements, and supporting analysis are due within 15 business days.

02 - The biggest nugget

The dilution pause

One sentence in the PR matters more than the headline: no new shares printed on the way to closing.

“Safe Harbor does not intend to draw on its existing equity line of credit with CREO Capital until the closing of the Proposed Transaction.”

PR, Key Terms (verbatim)

NO MORE DILUTION until closing. In plain terms: Safe Harbor plans to reach the $1 Nasdaq minimum by completing the merger, not by printing new shares on its dilution line.

Not by a reverse split. A split is a last resort only if the merger path does not get the price to $1.

Show the details

Why holders should care:

  • Supply stops growing into catalysts. Definitive agreement, Opifex financials, and the fairness opinion can land without freshly printed shares hitting the bid.
  • It protects the 15% math. Every share not printed pre-close is value that stays with existing holders instead of being spread thinner.
  • It is a signal, not just mechanics. A company planning to dilute its way to April does not volunteer a pause.
  • Paired with Series B converting at close (see §4), the capital structure is meant to be cleaned up at closing, not drip-fed into the market before it.

Honest caveat: the PR says “does not intend to draw.” That is stated intent in a non-binding term sheet, not a contractual lock in a definitive agreement yet. Watch for the same language to survive into the definitive deal. If it does, the pause is real. If it disappears, that is a tell.

03 - The math everyone’s wondering about

So what would a $50m valuation mean for the stock price?

Scenario math, not a price target. The PR states that current SHFS shareholders will own 15% of the new entity, fully diluted (Series B, warrants, options, and RSUs count too, not just common).

STEP 1 - FLOOR$50MOpifex valued at “not less than $50 million”
STEP 2 - SPLIT85% / 15%Opifex 85%, SHFS holders 15% fully diluted
STEP 3 - SHARES~5.54MSHFS fully diluted, post-split, from the filings
STEP 4 - COMBINED≈ 36.9MCombined shares in the new entity
~5.54M ÷ 15%
$50M ÷ ~36.9M combined shares
≈ $1.35
per share

$50M ÷ ~36.9M combined shares = ~$1.35 per share at the $50M floor, fully diluted. Still clears the $1 Nasdaq bid test, and that is before any value for the cannabis business or the CVR. That is the compliance path: the merger math gets above $1, with no reverse split needed to do it.

12.5% to SHFS (low end)~$1.13 / shareCombined shares about 44.3M
15% to SHFS (term sheet)~$1.35 / shareCombined shares about 36.9M
17.5% to SHFS (high end)~$1.58 / shareCombined shares about 31.6M

The 15% is not fixed. It adjusts to SHFS’s valuation at closing, supported by a fairness opinion. Hold value into closing and holders can end up with more than 15%.

Show how the flex works

The term sheet starts at 15% for existing SHFS holders and 85% for Opifex holders, but that split adjusts to reflect SHFS’s valuation at closing, supported by a fairness opinion. In plain terms, the split is re-measured when the deal closes, not locked at the numbers in the October PR. That is why the honest answer at the $50M floor is a range, about $1.13 to $1.58 a share, not just the $1.35 midpoint.

  • If SHFS holds its value into closing, holders get more. A higher SHFS valuation at closing can push the SHFS allocation above 15%, up to 17.5%. Opifex holders then get 82.5% instead of 85%. At the $50M floor, 17.5% works out to about $1.58 a share.
  • If SHFS’s valuation falls into closing, holders get less. A lower SHFS valuation at closing can pull the allocation down to 12.5%, with Opifex holders at 87.5%. At the $50M floor, 12.5% works out to about $1.13 a share.
  • It is relative valuation at closing, not just today’s price. A good week for the stock now does not lock in 17.5%, and a bad week now does not lock in 12.5%. What counts is where SHFS’s valuation stands relative to the deal values when the transaction closes, as tested by the fairness opinion process.

Think of it as a collar that protects both sides: Opifex is protected if SHFS is worth less at closing than it looked in October, and SHFS holders are rewarded if the company holds or builds its value on the way to closing.

Not 100% certain yet. The ~5.54M count comes from pre-split filings. The Q3 10-Q, expected around Nov 11, 2026, will confirm it, and this page will be updated with those numbers when filed.

Try it yourself: three sliders, one answer

Move all three. Combined shares and implied price update live.

Below $50M is not the deal as termed and would require renegotiation.

Our share count estimate uses the prior Series B conversion from the filings. That conversion is not necessarily the same conversion that would occur at closing, so the actual fully diluted share count could end up higher or lower. The slider lets you test that range.

$1.35Implied / share
36.9MCombined shares at 15.0%
$50.0MAnchor value
$1 ✓vs. $1 Nasdaq bid test
Show the math

How it works: combined shares = SHFS fully diluted shares ÷ the SHFS allocation percentage. Implied per share = Opifex anchor value ÷ combined shares. The Opifex counterpart is always 100% minus the SHFS allocation, so 15% to SHFS means 85% to Opifex, 17.5% to SHFS means 82.5% to Opifex, and 12.5% to SHFS means 87.5% to Opifex. Defaults ($50M, 5.54M shares, 15% allocation) give about 36.9M combined shares and about $1.35 a share. All before any closing raise and the 10% incentive plan reserve.

The $50M default is the term sheet floor: the term sheet contemplates an Opifex valuation of not less than $50 million, subject to an independent valuation and fairness opinion. The share count slider defaults to the filing-based ~5.54M; drag it up or down if you think Q3 moved the count.

Opifex anchor valueImplied / shareWhat it means
$5M$0.14Well below $1 fully diluted, a split would still be needed
$20M$0.54Still below $1 fully diluted, valuation has to hold near the floor
$50M, term-sheet floor$1.35Above the $1 Nasdaq bid test at 15%, about $1.13 to $1.58 across the flex range
$100M$2.71What upside looks like if valuation beats the floor

All rows use the filing-based ~5.54M fully diluted count at a 15% allocation (about 36.9M combined shares).

04 - Buried in the PR

Six more nuggets in the fine print

Holders keep upside

Contingent Value Right (CVR)

A CVR for SHFS holders tied to the cannabis business is being negotiated. Extra value on top of the 15%, not folded in and forgotten.

Clean-up at close

Series B converts at closing

All Series B Preferred converts into common at closing, subject to holder consents. The preferred overhang goes in one step.

Clock is ticking15 business days

Opifex financials due

Valuation, financial statements, and supporting analysis are due first, around mid-November. The $50M floor gets tested early.

Flex, both ways12.5% – 17.5%

15% is a starting point

The SHFS allocation adjusts to SHFS’s valuation at closing. Hold value in, get more. Full explainer in §3.

Exclusivity45 days

No shopping

Both sides locked in to negotiate this deal, not parallel ones. Exclusivity and confidentiality are the binding parts.

Real business underneath$36B+

Processed since inception, 41 states

More than $36 billion in cannabis-related transactions processed through Safe Harbor’s platform since inception, across 41 states and territories. That is cumulative volume processed, not revenue, not deposits held, and not annual volume. The business keeps operating post-close.

5 seats

New board

Newman as Chairman, 1 Opifex designee, 2 Opifex independents, 1 from Safe Harbor. Plus a 10% equity incentive reserve at closing.

$250B → ~$480B

The creator economy

Per the PR, citing Goldman Sachs Research: about $250B in 2023, could reach about $480B by 2027. Opifex acquires and operates creator businesses.

Opifex Media

05 - Let’s be straight about the split

The plan is compliance through the merger. A reverse split is a last resort.

The company is currently focused on reaching Nasdaq compliance through the merger, not through a reverse split, unless absolutely necessary. A reverse split is not the plan. It is the fallback only if the merger path does not get the share price to $1.

What the PR actually says

SHFS “would seek stockholder approval of a reverse stock split to the extent needed to meet Nasdaq’s bid price requirement.” Anyone saying a split is impossible has not read that paragraph. But “to the extent needed” is the key phrase: it is conditional, not the plan.

The current focus

The focus is reaching the $1 minimum through the merger. The floor math prices at about $1.35 fully diluted, above $1 with no split doing the work. A split also does not change ownership: 15% is 15% either way.

Bottom line: a reverse split is a last resort, not the plan. The plan is to get to $1 through the merger. A split only enters the picture if that path falls short and it becomes absolutely necessary. Fear the deal failing, not the split.
Show the details

Read the order of operations in the PR: first the merger, priced at about $1.35 a share fully diluted at the $50M floor, above the $1 Nasdaq bid test. The reverse split language sits behind that, as approval the company would seek only “to the extent needed” to meet the bid price requirement.

So the honest framing is: the company is currently focused on reaching Nasdaq compliance through the merger, not through a reverse split, unless absolutely necessary. If the merger path gets the share price to $1, no split is needed. A split is a last resort if the merger path does not get the share price to $1, not the plan and not the thesis.

The same PR paragraph also contemplates a possible registered equity financing to unaffiliated investors (if necessary) and a direct investment of up to $1.0M, alongside the split approval.

06 - The chairman

Greg Newman is not your typical penny-stock CEO

A four-decade, checkable record: founding teams, Fortune 500 product leadership, and a board seat through a landmark tech IPO. Verify every line; that is the point.

Greg Newman

Executive Chairman of Orbital Gridworks and Opifex Media

Chairman of the combined company

Greg Newman on LinkedIn Opifex Media Orbital Gridworks

His other new company, Orbital Gridworks, builds radioisotope heating systems and fission power generators for spacecraft and lunar missions. Newman would chair the combined company and its new 5-member board, bringing a four-decade record across founding teams, Fortune 500 product leadership, and a board seat through a landmark tech IPO.

1989–1993

Founding team, Macromedia

IPO in 1993, later sold to Adobe. The company that built the early multimedia web.

1993–1994

Led QuickTime at Apple

Product manager for QuickTime, foundational digital video technology.

1994–1996

Built Oracle Commerce Server

Senior Director of Product Management at Oracle, first wave of e-commerce.

1996–1999

Co-founded C2B, acquired by Inktomi

A real exit, to a real Nasdaq buyer, in 1998 (per PR).

2000–2005

Baidu: early investor + director through IPO

Early institutional investor and board director through Baidu’s 2005 Nasdaq IPO.

Today

Chairman of the combined company

Newman chairs Opifex Media and would chair the combined 5-member board.

Show the details

The honest nuance: Newman is a serial operator running several ventures at once (including space-power and other holdings), and Opifex Media as a holding company is newly assembled; its portfolio companies and revenue are still undisclosed. A credible chairman lowers the “is this real?” risk a lot. He does not replace the audited financials and fairness opinion. Both things are true, and the DD that matters is holding both at once.

Per CEO Terry Mendez in the PR: “Greg Newman brings decades of experience building and scaling technology companies.” Newman co-founded Integrity Partners, the vehicle behind the Baidu investment, and his Macromedia, Apple, and Oracle roles are checkable in Baidu’s own IPO history and the PR biography.

07 - What happens next

Catalyst timeline

~15 BUSINESS DAYS

Opifex valuation + financials

The $50M floor gets tested. Catalyst #1.

NEXT

Definitive agreement + fairness opinion

Non-binding becomes binding. Watch the dilution pause, CVR terms, and the final %.

Q3 - ~NOV 11

Safe Harbor earnings

First look at the core business after the announcement.

BEFORE CLOSE

Series B consents + stockholder vote

Conversion, deal, split, and incentive plan all need approvals. The S-4 will carry full terms.

BEFORE CLOSE

Nasdaq approval + any closing raise

Listing requirements at closing, plus up to $1.0M direct investment.

BY APR 19, 2027

Close, or the deadline

Target close is the same date the Nasdaq compliance period expires. The merger is the compliance plan; a reverse split is only the fallback if the price is still under $1.

SHFS specific catalysts (independent of the merger)

These are Safe Harbor catalysts on their own. They are independent of the Opifex merger and are NOT included in the $1.35 merger math in section 03. That math is based on the Opifex valuation only.

DEA RESCHEDULING

Schedule III and 280E

If cannabis moves to Schedule III, the 280E tax disallowance lifts for qualifying operators. That could improve operator cash flow, credit quality, and deposit stability for Safe Harbor. Initial briefs are due Oct 29, replies Nov 5. A final rule is realistically early 2027, and it is not guaranteed.

FEDERAL LEGISLATION

SAFER Banking Act

The SAFER Banking Act would encourage more banks to serve cannabis businesses and expand Safe Harbor's addressable market. Rescheduling alone does not replace it, and banks would still be looking for the clarity SAFER is meant to provide.

OPERATING BUSINESS

Deposits and Q3 earnings

Safe Harbor reported its best quarter-end deposits since April 2024 in its Oct 6 update. Q3 earnings around Nov 11 will update that picture.

08 - Risks, stated plainly

What could break this

Show the details
  • It is non-binding. Except for exclusivity and confidentiality, the term sheet “does not obligate either party to complete the Proposed Transaction” and there is “no assurance a definitive agreement will be executed.” That is the #1 risk, and the PR says it itself.
  • $50M is a floor, not an audit. It is “subject to an independent valuation and fairness opinion.” If Opifex’s delivered financials do not support it, the math in §3 reprices, downward.
  • Opifex financials are still undisclosed. No revenue, headcount, or named portfolio companies in the PR. Until the 15-business-day delivery lands, Opifex is a chairman, a strategy, and a valuation claim.
  • Consents and approvals can fail. Series B holder consents, stockholder approval, Nasdaq approval, due diligence, and any required financing are all closing conditions.
  • Closing dilution still exists. The dilution pause covers the road to closing. At closing there may be a registered raise, the up-to-$1.0M direct investment, and a 10% incentive reserve, all disclosed, all dilutive to the headline share count.
  • Position and liquidity risk is personal. SHFS is thinly traded. Any large holder exiting at size will move the price against themselves; that is a trading fact, not a deal term.